

Prior Authorization

Certain drugs require prior authorization to help promote safe, quality and affordable pharmacy care. Your doctor will need to submit a prior authorization request to Prime Therapeutics, which must be approved before you can continue to receive coverage for these drugs.

The Prior Authorization form that your physician will need to complete to request an approval can be found on the MyPrime website.

Quantity Limit Consideration

Within the Prior Authorization program, Quantity Limit may apply. If there is medical reason why you need an amount that is greater than what is allowed, your physician can fill out a Quantity Limit prior authorization form for you and send it to Prime Therapeutics. This form can be found on the MyPrime.com website.

Prior Authorization Program	Preferred Product(s)	Drug(s) in Program
Afrezza		AFREZZA
Amantadine ER		GOCOVRI
Amantadine ER		OSMOLEX ER
Amifampridine		FIRDAPSE
Amifampridine		RUZURGI
Ampyra		AMPYRA
Ampyra		dalfampridine er
Androgen Anabolic Steroids		ANADROL-50
Androgen Anabolic Steroids	Preferred Product: Through generic	ANDRODERM
Androgen Anabolic Steroids	Preferred Product: Through generic	ANDROGEL
Androgen Anabolic Steroids	Preferred Product: Through generic	ANDROGEL PUMP
Androgen Anabolic Steroids		ANDROID
Androgen Anabolic Steroids	Preferred Product: Through generic	FORTESTA
Androgen Anabolic Steroids		METHITEST
Androgen Anabolic Steroids		METHYLTESTOSTERONE

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Androgen Anabolic Steroids	Preferred Product: Through generic	NATESTO
Androgen Anabolic Steroids		OXANDRIN
Androgen Anabolic Steroids	Preferred Product: Through generic	STRIANT
Androgen Anabolic Steroids	Preferred Product: Through generic	TESTIM
Androgen Anabolic Steroids	Preferred Product: Through generic	TESTOSTERONE
Androgen Anabolic Steroids	Preferred Product: Through generic	TESTOSTERONE PUMP
Androgen Anabolic Steroids		TESTRED
Androgen Anabolic Steroids	Preferred Product: Through generic	VOGELXO
Androgen Anabolic Steroids	Preferred Product: Through generic	VOGELXO PUMP
Androgen Anabolic Steroids		danazol
Androgen Anabolic Steroids		oxandrolone
Androgen Anabolic Steroids	Preferred Product: Through generic	testosterone
Androgen Anabolic Steroids	Preferred Product: Through generic	testosterone pump
Androgen Anabolic Steroids	Preferred Product: Through generic	testosterone topical solution
Antifungal (Lamisil/Sporanox/Penlac)		JUBLIA
Antifungal (Lamisil/Sporanox/Penlac)		KERYDIN
Antifungal (Lamisil/Sporanox/Penlac)		PENLAC NAIL LACQUER
Antifungal (Lamisil/Sporanox/Penlac)		ciclodan
Antifungal (Lamisil/Sporanox/Penlac)		ciclopirox nail lacquer
Arikayce		ARIKAYCE
Benlysta		BENLYSTA
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	ACTEMRA
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel,	ACTEMRA ACTPEN

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

	Humira, Rinvoq, Skyrizi, Stelara, Tremfya	
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	CIMZIA
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	CIMZIA STARTER KIT
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	COSENTYX
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	COSENTYX SENSOREADY PEN
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	ENBREL
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	ENBREL MINI
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	ENBREL SURECLICK
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	HUMIRA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	HUMIRA PEN
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	HUMIRA PEN-CD/UC/HS STARTER
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	HUMIRA PEN-PS/UV STARTER
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	KEVZARA
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	KINERET
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	OLUMIANT
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	ORENCIA
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq,	ORENCIA CLICKJECT

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

	Skyrizi, Stelara, Tremfya	
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	OTEZLA
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	RINVOQ
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	SILIQ
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	SIMPONI
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	SKYRIZI
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	STELARA
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	TALTZ
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	TREMFYA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	XELJANZ
Biologic Immunomodulators	Preferred Products: Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, Stelara, Tremfya	XELJANZ XR
Bonjesta Diclegis		BONJESTA
Bonjesta Diclegis		DICLEGIS
Bonjesta Diclegis		doxylamine succinate/pyridoxine hydrochloride
Buprenorphine Opioid Dependence		buprenorphine hcl
Cannabidiol		EPIDIOLEX
Carbaglu		CARBAGLU
CFTR		KALYDECO
CFTR		ORKAMBI
CFTR		SYMDEKO
CFTR		TRIKAFTA
CGRP	Preferred Products: Aimovig, Emgality	AIMOVIG
CGRP	Preferred Products: Aimovig, Emgality	AJOVY
CGRP	Preferred Products: Aimovig, Emgality	EMGALITY
Circadian Rhythm Disorder		HETLIOZ
Constipation Agents	Preferred Products: Symproic, Trulance	AMITIZA
Constipation Agents	Preferred Products: Symproic, Trulance	LINZESS
Constipation Agents	Preferred Products: Symproic, Trulance	MOTTEGRITY
Constipation Agents	Preferred Products: Symproic, Trulance	MOVANTIK
Constipation Agents	Preferred Products: Symproic, Trulance	RELISTOR
Constipation Agents	Preferred Products: Symproic, Trulance	SYMPROIC
Constipation Agents	Preferred Products: Symproic, Trulance	TRULANCE

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Constipation Agents	Preferred Products: Symproic, Trulance	ZELNORM
Diclofenac Fluorouracil Imiquimod Ingenol		ALDARA
Diclofenac Fluorouracil Imiquimod Ingenol		CARAC
Diclofenac Fluorouracil Imiquimod Ingenol		EFUDEX
Diclofenac Fluorouracil Imiquimod Ingenol		FLUOROPLEX
Diclofenac Fluorouracil Imiquimod Ingenol		FLUOROURACIL
Diclofenac Fluorouracil Imiquimod Ingenol		IMIQUIMOD PUMP
Diclofenac Fluorouracil Imiquimod Ingenol		PICATO
Diclofenac Fluorouracil Imiquimod Ingenol		TOLAK
Diclofenac Fluorouracil Imiquimod Ingenol		ZYCLARA
Diclofenac Fluorouracil Imiquimod Ingenol		ZYCLARA PUMP
Diclofenac Fluorouracil Imiquimod Ingenol		diclofenac sodium
Elmiron		ELMIRON
Emflaza		EMFLAZA
Endari		ENDARI
Flector		DICLOFENAC EPOLAMINE
Flector		FLECTOR
Galafold		GALAFOLD
Gattex		GATTEX
Growth Hormone	Preferred Product: Norditropin	GENOTROPIN
Growth Hormone	Preferred Product: Norditropin	GENOTROPIN MINIQUEICK
Growth Hormone	Preferred Product: Norditropin	HUMATROPE
Growth Hormone	Preferred Product: Norditropin	HUMATROPE COMBO PACK
Growth Hormone	Preferred Product: Norditropin	NORDITROPIN FLEXPRO

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Growth Hormone	Preferred Product: Norditropin	NUTROPIN AQ NUSPIN 10
Growth Hormone	Preferred Product: Norditropin	NUTROPIN AQ NUSPIN 20
Growth Hormone	Preferred Product: Norditropin	NUTROPIN AQ NUSPIN 5
Growth Hormone	Preferred Product: Norditropin	OMNITROPE
Growth Hormone	Preferred Product: Norditropin	SAIZEN
Growth Hormone	Preferred Product: Norditropin	SAIZEN CLICK.EASY
Growth Hormone	Preferred Product: Norditropin	SAIZENPREP RECONSTITUTIONKIT
Growth Hormone	Preferred Product: Norditropin	SEROSTIM
Growth Hormone	Preferred Product: Norditropin	ZOMACTON
Growth Hormone	Preferred Product: Norditropin	ZORBTIVE
hATTR Amyloidosis		TEGSEDI
HCN Channel Blocker		CORLANOR
Hemophilia Agents		ADVATE
Hemophilia Agents		ADYNOVATE
Hemophilia Agents		AFSTYLA
Hemophilia Agents		ALPHANATE/VON WILLEBRAND FACTOR COMPLEX/HUMAN
Hemophilia Agents		ALPHANINE SD
Hemophilia Agents		ALPROLIX
Hemophilia Agents		BEBULIN
Hemophilia Agents		BENEFIX
Hemophilia Agents		COAGADEX
Hemophilia Agents		CORIFACT
Hemophilia Agents		ELOCTATE
Hemophilia Agents		HELIXATE FS
Hemophilia Agents		HEMLIBRA
Hemophilia Agents		HEMOPIL M
Hemophilia Agents		HUMATE-P
Hemophilia Agents		IDELVION
Hemophilia Agents		IXINITY
Hemophilia Agents		JIVI

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Hemophilia Agents		KOATE
Hemophilia Agents		KOATE-DVI
Hemophilia Agents		KOGENATE FS
Hemophilia Agents		KOGENATE FS BIO-SET
Hemophilia Agents		KOVALTRY
Hemophilia Agents		MONOCLATE-P
Hemophilia Agents		MONONINE
Hemophilia Agents		NOVOEIGHT
Hemophilia Agents		NOVOSEVEN RT
Hemophilia Agents		NUWIQ
Hemophilia Agents		OBIZUR
Hemophilia Agents		PROFILNINE
Hemophilia Agents		PROFILNINE SD
Hemophilia Agents		REBINYN
Hemophilia Agents		RECOMBINATE
Hemophilia Agents		RIXUBIS
Hemophilia Agents		TRETTEN
Hemophilia Agents		VONVENDI
Hemophilia Agents		WILATE
Hemophilia Agents		XYNTHA
Hemophilia Agents		XYNTHA SOLOFUSE
Hepatitis B/C		PEGASYS
Hepatitis B/C		PEGASYS PROCLICK
Hepatitis B/C		PEGINTRON
Hepatitis C Agents	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, Sovaldi, and Vosevi	DAKLINZA
Hepatitis C Agents	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, Sovaldi, and Vosevi	EPCLUSA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Hepatitis C Agents	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, Sovaldi, and Vosevi	HARVONI
Hepatitis C Agents	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, Sovaldi, and Vosevi	LEDIPASVIR/SOFOSBUVIR
Hepatitis C Agents	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, Sovaldi, and Vosevi	MAVYRET
Hepatitis C Agents	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, Sovaldi, and Vosevi	OLYSIO
Hepatitis C Agents	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, Sovaldi, and Vosevi	SOFOSBUVIR/VELPATASVIR
Hepatitis C Agents	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, Sovaldi, and Vosevi	SOVALDI

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

	generic ledipasvir/sofosbuvir, Harvoni, Mavyret, Sovaldi, and Vosevi	
Hepatitis C Agents	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, Sovaldi, and Vosevi	TECHNIVIE
Hepatitis C Agents	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, Sovaldi, and Vosevi	VIEKIRA PAK
Hepatitis C Agents	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, Sovaldi, and Vosevi	VIEKIRA XR
Hepatitis C Agents	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, Sovaldi, and Vosevi	VOSEVI
Hepatitis C Agents	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, Sovaldi, and Vosevi	ZEPATIER

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Hereditary Angioedema	BERINERT
Hereditary Angioedema	FIRAZYR
Hereditary Angioedema	HAEGARDA
Hereditary Angioedema	KALBITOR
Hereditary Angioedema	RUCONEST
Hereditary Angioedema	TAKHZYRO
Hereditary Angioedema	icatibant acetate
HoFH Agents	JUXTAPID
HoFH Agents	KYNAMRO
HP Acthar	ACTHAR
HSDD	Addyi
HSDD	VYLEESI
Hyperhidrosis	QBREXZA
Idiopathic Pulmonary Fibrosis	ESBRIET
Idiopathic Pulmonary Fibrosis	OFEV
Immune Globulins	CUVITRU
Immune Globulins	GAMMAGARD LIQUID
Immune Globulins	GAMMAKED
Immune Globulins	GAMUNEX-C
Immune Globulins	HIZENTRA
Immune Globulins	HYQVIA
Immune Globulins	CUTAQUIG
Immune Globulins	XEMBIFY
Inhaled Antibiotics	BETHKIS
Inhaled Antibiotics	CAYSTON
Inhaled Antibiotics	KITABIS PAK
Inhaled Antibiotics	TOBI
Inhaled Antibiotics	TOBI PODHALER
Inhaled Antibiotics	TOBRAMYCIN
Inhaled Antibiotics	tobramycin
Interleukin (IL)-1 Inhibitors	ARCALYST
Interleukin (IL)-1 Inhibitors	ILARIS
Interleukin (IL)-4 Inhibitor	DUPIXENT
Interleukin (IL)-5 Inhibitors	FASENRA PEN
Interleukin (IL)-5 Inhibitors	NUCALA
Jynarque	JYNARQUE
Keveyis	KEVEYIS
Korlym	KORLYM
Lucemyra	LUCEMYRA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Lyrica CR		LYRICA CR
Myalept		MYALEPT
Natpara		NATPARA
Neurotrophic Keratitis		OXERVATE
Nocturia		NOCDURNA
Nocturia		NOCTIVA
Nothera		NORTHERA
Ocaliva		OCALIVA
Ophthalmic Immunomodulators		CEQUA
Ophthalmic Immunomodulators		RESTASIS
Ophthalmic Immunomodulators		RESTASIS MULTIDOSE
Ophthalmic Immunomodulators		XIIDRA
Opioids ER		ARYMO ER
Opioids ER		BELBUCA
Opioids ER		BUPRENORPHINE
Opioids ER		BUTRANS
Opioids ER		CONZIP
Opioids ER		DURAGESIC
Opioids ER		EMBEDA
Opioids ER		EXALGO
Opioids ER		HYSINGLA ER
Opioids ER		KADIAN
Opioids ER		MORPHABOND ER
Opioids ER		MORPHINE SULFATE ER
Opioids ER		MS CONTIN
Opioids ER		NUCYNTA ER
Opioids ER		OPANA ER (CRUSH RESISTANT)
Opioids ER		OXYCODONE HCL ER
Opioids ER		OXYCODONE HYDROCHLORIDE ER
Opioids ER		OXYCONTIN
Opioids ER		OXYMORPHONE HYDROCHLORIDE ER
Opioids ER		OXYMORPHONE HYDROCHLORIDEER
Opioids ER		TRAMADOL HCL ER
Opioids ER		XTAMPZA ER
Opioids ER		ZOHYDRO ER
Opioids ER		buprenorphine

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Opioids ER		fentanyl
Opioids ER		hydromorphone hcl er
Opioids ER		hydromorphone hydrochloride
Opioids ER		hydromorphone hydrochloride er
Opioids ER		morphine sulfate er
Opioids ER		tramadol hcl er
Opioids IR Duration Limit		ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE
Opioids IR Duration Limit		ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE BITARTRATE
Opioids IR Duration Limit		APADAZ
Opioids IR Duration Limit		ASPIRIN-CAFFEINE-DIHYDROCODEINE
Opioids IR Duration Limit		BENZHYDROCODONE/ACETAMINOPHEN
Opioids IR Duration Limit		BUTALBITAL/ACETAMINOPHEN
Opioids IR Duration Limit		CODEINE SULFATE
Opioids IR Duration Limit		DEMEROL
Opioids IR Duration Limit		DILAUDID
Opioids IR Duration Limit		DOLOPHINE
Opioids IR Duration Limit		DVORAH
Opioids IR Duration Limit		FIORICET/CODEINE
Opioids IR Duration Limit		FIORINAL/CODEINE #3
Opioids IR Duration Limit		HYDROCODONE BITARTRATE/ACETAMINOPHEN
Opioids IR Duration Limit		IBUDONE
Opioids IR Duration Limit		LEVORPHANOL TARTRATE
Opioids IR Duration Limit		LORTAB
Opioids IR Duration Limit		MEPERIDINE HCL
Opioids IR Duration Limit		METHADONE HCL
Opioids IR Duration Limit		METHADOSE
Opioids IR Duration Limit		METHADOSE SUGAR-FREE
Opioids IR Duration Limit		MORPHINE SULFATE
Opioids IR Duration Limit		NALOCET
Opioids IR Duration Limit		NORCO
Opioids IR Duration Limit		NUCYNTA
Opioids IR Duration Limit		OPANA
Opioids IR Duration Limit		OXAYDO
Opioids IR Duration Limit		OXYCODONE/ACETAMINOPHEN
Opioids IR Duration Limit		OXYCODONE/ASPIRIN
Opioids IR Duration Limit		OXYCODONE/IBUPROFEN
Opioids IR Duration Limit		PERCOCET
Opioids IR Duration Limit		PRIMLEV

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Opioids IR Duration Limit		ROXICODONE
Opioids IR Duration Limit		SYNALGOS-DC
Opioids IR Duration Limit		TREZIX
Opioids IR Duration Limit		TYLENOL/CODEINE #2
Opioids IR Duration Limit		TYLENOL/CODEINE #3
Opioids IR Duration Limit		TYLENOL/CODEINE #4
Opioids IR Duration Limit		ULTRACET
Opioids IR Duration Limit		ULTRAM
Opioids IR Duration Limit		XODOL
Opioids IR Duration Limit		ZAMICET
Opioids IR Duration Limit		acetaminophen/codeine
Opioids IR Duration Limit		acetaminophen/codeine phosphate
Opioids IR Duration Limit		ascomp/codeine
Opioids IR Duration Limit		butalbital/acetaminophen/caffeine/codeine
Opioids IR Duration Limit		butalbital/aspirin/caffeine/codeine
Opioids IR Duration Limit		butorphanol tartrate
Opioids IR Duration Limit		codeine sulfate
Opioids IR Duration Limit		endocet
Opioids IR Duration Limit		hydrocodone bitartrate/acetaminophen
Opioids IR Duration Limit		hydrocodone/acetaminophen
Opioids IR Duration Limit		hydrocodone/ibuprofen
Opioids IR Duration Limit		hydromorphone hcl
Opioids IR Duration Limit		ibudone
Opioids IR Duration Limit		levorphanol tartrate
Opioids IR Duration Limit		lorcet
Opioids IR Duration Limit		lorcet hd
Opioids IR Duration Limit		lorcet plus
Opioids IR Duration Limit		meperidine hcl
Opioids IR Duration Limit		methadone hcl
Opioids IR Duration Limit		methadone hcl intensol
Opioids IR Duration Limit		methadone hydrochloride
Opioids IR Duration Limit		methadose
Opioids IR Duration Limit		morphine sulfate
Opioids IR Duration Limit		oxycodone hcl
Opioids IR Duration Limit		oxycodone hydrochloride
Opioids IR Duration Limit		oxycodone/acetaminophen
Opioids IR Duration Limit		oxycodone/aspirin
Opioids IR Duration Limit		oxymorphone hydrochloride
Opioids IR Duration Limit		panlor

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Opioids IR Duration Limit		pentazocine/naloxone hcl
Opioids IR Duration Limit		tramadol hcl
Opioids IR Duration Limit		tramadol hydrochloride/acetaminophen
Opioids IR Duration Limit		vicodin
Opioids IR Duration Limit		vicodin es
Opioids IR Duration Limit		vicodin hp
Opioids IR Duration Limit		xylon
Oral PAH	Preferred Product: Through generic	ADCIRCA
Oral PAH		ADEMPAS
Oral PAH		LETAIRIS
Oral PAH		OPSUMIT
Oral PAH		ORENITRAM
Oral PAH	Preferred Product: Through generic	REVATIO
Oral PAH		TRACLEER
Oral PAH		TYVASO
Oral PAH		TYVASO REFILL
Oral PAH		TYVASO STARTER
Oral PAH		UPTRAVI
Oral PAH		VENTAVIS
Oral PAH		ambrisentan
Oral PAH		bosentan
Oral PAH		sildenafil citrate
Oral PAH		tadalafil
Orilissa		ORILISSA
Parathyroid Hormone Analog for Osteoporosis	Preferred Product: Tymlos	FORTEO
Parathyroid Hormone Analog for Osteoporosis	Preferred Product: Tymlos	TYMLOS
PCSK-9 Inhibitors	Preferred Product: Repatha	REPATHA
PCSK-9 Inhibitors	Preferred Product: Repatha	REPATHA PUSHTRONEX SYSTEM
PCSK-9 Inhibitors	Preferred Product: Repatha	REPATHA SURECLICK
PCSK-9 Inhibitors	Preferred Product: Repatha	PRALUENT
Phenylketonuria		KUVAN
Phenylketonuria		PALYNZIQ
Procysbi		PROCYSBI

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Pseudobulbar Affect		NUDEXTA
Riluzole		RILUTEK
Riluzole		TIGLUTIK
SA Oncology		AFINITOR
SA Oncology		AFINITOR DISPERZ
SA Oncology		ALECENSA
SA Oncology		ALUNBRIG
SA Oncology		BALVERSA
SA Oncology		BOSULIF
SA Oncology		BRAFTOVI
SA Oncology		CABOMETYX
SA Oncology		CALQUENCE
SA Oncology		CAPRELSA
SA Oncology		COMETRIQ
SA Oncology		COPIKTRA
SA Oncology		COTELLIC
SA Oncology		DAURISMO
SA Oncology		ERIVEDGE
SA Oncology		ERLEADA
SA Oncology		FARYDAK
SA Oncology		GILOTRIF
SA Oncology		GLEEVEC
SA Oncology		HEXALEN
SA Oncology		HYCAMTIN
SA Oncology		IBRANCE
SA Oncology		ICLUSIG
SA Oncology		IDHIFA
SA Oncology		IMBRUVICA
SA Oncology		INLYTA
SA Oncology		INREBIC
SA Oncology		IRESSA
SA Oncology		JAKAFI
SA Oncology	Preferred Product for Advanced or Metastatic Breast Cancer: Ibrance, Verzenio	KISQALI
SA Oncology	Preferred Product for Advanced or	KISQALI FEMARA 200 DOSE

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

	Metastatic Breast Cancer: Ibrance, Verzenio	
SA Oncology	Preferred Product for Advanced or Metastatic Breast Cancer: Ibrance, Verzenio	KISQALI FEMARA 400 DOSE
SA Oncology	Preferred Product for Advanced or Metastatic Breast Cancer: Ibrance, Verzenio	KISQALI FEMARA 600 DOSE
SA Oncology		LENVIMA
SA Oncology		LONSURF
SA Oncology		LORBRENA
SA Oncology		LYNPARZA
SA Oncology		LYSODREN
SA Oncology		MATULANE
SA Oncology		MEKINIST
SA Oncology		MEKTOVI
SA Oncology		NERLYNX
SA Oncology		NEXAVAR
SA Oncology		NINLARO
SA Oncology		NUBEQA
SA Oncology		ODOMZO
SA Oncology		PIQRAY 200MG DAILY DOSE
SA Oncology		PIQRAY 250MG DAILY DOSE
SA Oncology		PIQRAY 300MG DAILY DOSE
SA Oncology		POMALYST
SA Oncology		REVLIMID
SA Oncology		ROZLYTREK
SA Oncology		RUBRACA
SA Oncology		RYDAPT
SA Oncology		SPRYCEL
SA Oncology		STIVARGA
SA Oncology		SUTENT
SA Oncology		SYLATRON
SA Oncology		TAFINLAR
SA Oncology		TAGRISSO
SA Oncology		TALZENNA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

SA Oncology		TARCEVA
SA Oncology		TARGRETIN
SA Oncology		TASIGNA
SA Oncology		TEMODAR
SA Oncology		THALOMID
SA Oncology		TIBSOVO
SA Oncology		TURALIO
SA Oncology		TYKERB
SA Oncology		VENCLEXTA
SA Oncology		VENCLEXTA STARTING PACK
SA Oncology		VERZENIO
SA Oncology		VITRAKVI
SA Oncology		VIZIMPRO
SA Oncology		VOTRIENT
SA Oncology		XALKORI
SA Oncology		XELODA
SA Oncology		XOSPATA
SA Oncology		XPOVIO 100 MG ONCE WEEKLY
SA Oncology		XPOVIO 60 MG ONCE WEEKLY
SA Oncology		XPOVIO 80 MG ONCE WEEKLY
SA Oncology		XPOVIO 80 MG TWICE WEEKLY
SA Oncology		XTANDI
SA Oncology		YONSA
SA Oncology		ZEJULA
SA Oncology		ZELBORAF
SA Oncology		ZOLINZA
SA Oncology		ZYDELIG
SA Oncology		ZYKADIA
SA Oncology		ZYTIGA
SA Oncology		abiraterone acetate
SA Oncology		bexarotene
SA Oncology		capecitabine
SA Oncology		erlotinib hydrochloride
SA Oncology		imatinib mesylate
SA Oncology		temozolomide
SA Oncology		tretinoin
Samsca		SAMSCA
Signifor		SIGNIFOR
Sodium Oxybate		XYREM

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

SSIA		NUPLAZID
Strensiq		STRENSIQ
Substrate Reduction Therapy		CERDELGA
Substrate Reduction Therapy		ZAVESCA
Substrate Reduction Therapy		miglustat
Sucralfate Suspension		CARAFATE
Sunosi		SUNOSI
Tafamadis		VYNDAQEL
Tafamadis		VYNDAMAX
Thrombopoietin Receptor Agonists		DOPTELET
Thrombopoietin Receptor Agonists		MULPLETA
Thrombopoietin Receptor Agonists		PROMACTA
Thrombopoietin Receptor Agonists		TAVALISSE
Topical Doxepin		DOXEPIN HYDROCHLORIDE
Topical Doxepin		PRUDOXIN
Topical Doxepin		ZONALON
Topiramate ER		QUDEXY XR
Topiramate ER		TOPIRAMATE ER
Topiramate ER		TROKENDI XR
Transmucosal Immediate Release Fentanyl	Preferred Product: Through generic	ABSTRAL
Transmucosal Immediate Release Fentanyl	Preferred Product: Through generic	ACTIQ
Transmucosal Immediate Release Fentanyl	Preferred Product: Through generic	FENTANYL CITRATE
Transmucosal Immediate Release Fentanyl	Preferred Product: Through generic	FENTORA
Transmucosal Immediate Release Fentanyl	Preferred Product: Through generic	LAZANDA
Transmucosal Immediate Release Fentanyl	Preferred Product: Through generic	SUBSYS
Transmucosal Immediate Release Fentanyl		fentanyl citrate oral transmucosal
URAT1 Inhibitor		DUZALLO
URAT1 Inhibitor		ZURAMPIC
Urea Cycle Disorders		BUPHENYL
Urea Cycle Disorders		RAVICTI

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Urea Cycle Disorders		sodium phenylbutyrate
Weight Loss Agents		ADIPEX-P
Weight Loss Agents		BELVIQ
Weight Loss Agents		BELVIQ XR
Weight Loss Agents		BENZPHETAMINE HCL
Weight Loss Agents		CONTRAVE
Weight Loss Agents		DIETHYLPROPION HCL
Weight Loss Agents		DIETHYLPROPION HCL ER
Weight Loss Agents		LOMAIRA
Weight Loss Agents		PHENDIMETRAZINE TARTRATE ER
Weight Loss Agents		QSYMIA
Weight Loss Agents		REGIMEX
Weight Loss Agents		SAXENDA
Weight Loss Agents		XENICAL
Weight Loss Agents		benzphetamine hcl
Weight Loss Agents		diethylpropion hcl
Weight Loss Agents		diethylpropion hcl er
Weight Loss Agents		phendimetrazine tartrate
Weight Loss Agents		phentermine hcl
Weight Loss Agents		phentermine hydrochloride
Xermelo		XERMELO

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.